JDJiacong Du

Jiacong Du

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiacong Du has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Outcome and Exposure Polygenic Risk Scores Can Help Reduce Information Bias and Selection Bias in Regression Estimates From Biobank Data

    by Maxwell Salvatore, Ritoban Kundu, Jiacong Du, Christopher R. Friese, Alison M. Mondul, David Hanauer, Haidong Lu, Celeste Leigh Pearce, Bhramar Mukherjee

    Electronic health records (EHRs) are valuable sources of data but are susceptible to biases from missing data and sample selection, often due to clinically informative visiting processes and non‐probability sampling. This research explores whether genetic data, typically measured on nearly all participants in EHR‐linked biobanks, can be used to mitigate these biases. Simulations were performed under conditions of missing completely at random (MCAR), missing at random (MAR), and missing not at random (MNAR) within random and biased sampling frameworks. We evaluated PRS‐informed imputation, PRS‐uninformed imputation, and complete case analysis across these scenarios in terms of bias, coverage, and root mean square error (RMSE) of the regression coefficient estimates. A real‐world example using data from the Michigan Genomics Initiative (MGI, n = 68,063) compared the effectiveness of these methods against national benchmark estimates. PRS‐informed imputation generally reduced bias and RMSE and improved coverage, particularly under MAR conditions in random samples. In analyses of biased samples of n = 10,000 with MAR exposure‐only missingness, weighted, PRS‐informed imputation analyses showed substantially lower percent bias (0.6%) and closer to nominal coverage (89.1%) compared to weighted, complete case analyses (9.4%; 74.3%). The MGI estimates showed that PRS‐informed approaches aligned more closely with national benchmarks than unweighted complete case analysis. Leveraging genetic data with sample weighting can help reduce bias in outcome‐exposure association estimates derived from biobank data. When available, researchers should consider including PRS for imputation and survey methods for sample weighting when estimating outcome‐exposure association coefficients in a target population of interest, recognizing that benefits may vary by outcome and data structure.

  • Outcome adaptive propensity score methods for handling censoring and high-dimensionality: Application to insurance claims

    by Jiacong Du, Youfei Yu, Min Zhang, Zhenke Wu, Andrew M Ryan, Bhramar Mukherjee

    Propensity scores are commonly used to reduce the confounding bias in non-randomized observational studies for estimating the average treatment effect. An important assumption underlying this approach is that all confounders that are associated with both the treatment and the outcome of interest are measured and included in the propensity score model. In the absence of strong prior knowledge about potential confounders, researchers may agnostically want to adjust for a high-dimensional set of pre-treatment variables. As such, variable selection procedure is needed for propensity score estimation. In addition, studies show that including variables related to treatment only in the propensity score model may inflate the variance of the treatment effect estimators, while including variables that are predictive of only the outcome can improve efficiency. In this article, we propose to incorporate outcome-covariate relationship in the propensity score model by including the predicted binary outcome probability as a covariate. Our approach can be easily adapted to an ensemble of variable selection methods, including regularization methods and modern machine-learning tools based on classification and regression trees. We evaluate our method to estimate the treatment effects on a binary outcome, which is possibly censored, across multiple treatment groups. Simulation studies indicate that incorporating outcome probability for estimating the propensity scores can improve statistical efficiency and protect against model misspecification. The proposed methods are applied to a cohort of advanced-stage prostate cancer patients identified from a private insurance claims database for comparing the adverse effects of four commonly used drugs for treating castration-resistant prostate cancer.


  • Open Access

    Reducing Information and Selection Bias in EHR-Linked Biobanks via Genetics-Informed Multiple Imputation and Sample Weighting

    by Maxwell Salvatore, Ritoban Kundu, Jiacong Du, Christopher R Friese, Alison M Mondul, David Hanauer, Haidong Lu, Celeste Leigh Pearce, Bhramar Mukherjee

    Electronic health records (EHRs) are valuable for public health and clinical research but are prone to many sources of bias, including missing data and non-probability selection. Missing data in EHRs is complex due to potential non-recording, fragmentation, or clinically informative absences. This study explores whether polygenic risk score (PRS)-informed multiple imputation for missing traits, combined with sample weighting, can mitigate missing data and selection biases in estimating disease-exposure associations. Simulations were conducted for missing completely at random (MCAR), missing at random (MAR), and missing not at random (MNAR) conditions under different sampling mechanisms. PRS-informed multiple imputation showed generally lower bias, particularly when combined with sample weighting. For example, in biased samples of 10,000 with exposure and outcome MAR data, PRS-informed imputation had lower percent bias (3.8%) and better coverage rate (0.883) compared to PRS-uninformed (4.5%; 0.877) and complete case analyses (10.3%; 0.784) in covariate-adjusted, weighted, multiple imputation scenarios. In a case study using Michigan Genomics Initiative (n=50,026) data, PRS-informed imputation aligned more closely with a sample-weighted All of Us-derived benchmark than analyses ignoring missing data and selection bias. Researchers should consider leveraging genetic data and sample weighting to address biases from missing data and non-probability sampling in biobanks.


  • Open Access

    Uncovering associations between pre-existing conditions and COVID-19 Severity: A polygenic risk score approach across three large biobanks

    by Lars G. Fritsche, Kisung Nam, Jiacong Du, Ritoban Kundu, Maxwell Salvatore, Xu Shi, Seunggeun Lee, Stephen Burgess, Bhramar Mukherjee

    Objective: To overcome the limitations associated with the collection and curation of COVID-19 outcome data in biobanks, this study proposes the use of polygenic risk scores (PRS) as reliable proxies of COVID-19 severity across three large biobanks: the Michigan Genomics Initiative (MGI), UK Biobank (UKB), and NIH All of Us. The goal is to identify associations between pre-existing conditions and COVID-19 severity. Methods: Drawing on a sample of more than 500,000 individuals from the three biobanks, we conducted a phenome-wide association study (PheWAS) to identify associations between a PRS for COVID-19 severity, derived from a genome-wide association study on COVID-19 hospitalization, and clinical pre-existing, pre-pandemic phenotypes. We performed cohort-specific PRS PheWAS and a subsequent fixed-effects meta-analysis. Results: The current study uncovered 23 pre-existing conditions significantly associated with the COVID-19 severity PRS in cohort-specific analyses, of which 21 were observed in the UKB cohort and two in the MGI cohort. The meta-analysis yielded 27 significant phenotypes predominantly related to obesity, metabolic disorders, and cardiovascular conditions. After adjusting for body mass index, several clinical phenotypes, such as hypercholesterolemia and gastrointestinal disorders, remained associated with an increased risk of hospitalization following COVID-19 infection. Conclusion: By employing PRS as a proxy for COVID-19 severity, we corroborated known risk factors and identified novel associations between pre-existing clinical phenotypes and COVID-19 severity. Our study highlights the potential value of using PRS when actual outcome data may be limited or inadequate for robust analyses.


  • Open Access

    Methods for Mediation Analysis with High-Dimensional DNA Methylation Data: Possible Choices and Comparison

    by Dylan Clark-Boucher, Xiang Zhou, Jiacong Du, Yongmei Liu, Belinda L Needham, Jennifer A Smith, Bhramar Mukherjee

    Epigenetic researchers often evaluate DNA methylation as a mediator between social/environmental exposures and disease, but modern statistical methods for jointly evaluating many mediators have not been widely adopted. We compare seven methods for high-dimensional mediation analysis with continuous outcomes through both diverse simulations and analysis of DNAm data from a large national cohort in the United States, while providing an R package for their implementation. Among the considered choices, the best-performing methods for detecting active mediators in simulations are the Bayesian sparse linear mixed model by Song et al. (2020) and high-dimensional mediation analysis by Gao et al. (2019); while the superior methods for estimating the global mediation effect are high-dimensional linear mediation analysis by Zhou et al. (2021) and principal component mediation analysis by Huang and Pan (2016). We provide guidelines for epigenetic researchers on choosing the best method in practice and offer suggestions for future methodological development.


  • Open Access

    Methods for large‐scale single mediator hypothesis testing: Possible choices and comparisons

    by Jiacong Du, Xiang Zhou, Dylan Clark‐Boucher, Wei Hao, Yongmei Liu, Jennifer A. Smith, Bhramar Mukherjee

    Mediation hypothesis testing for a large number of mediators is challenging due to the composite structure of the null hypothesis, (: effect of the exposure on the mediator after adjusting for confounders; : effect of the mediator on the outcome after adjusting for exposure and confounders). In this paper, we reviewed three classes of methods for large‐scale one at a time mediation hypothesis testing. These methods are commonly used for continuous outcomes and continuous mediators assuming there is no exposure‐mediator interaction so that the product has a causal interpretation as the indirect effect. The first class of methods ignores the impact of different structures under the composite null hypothesis, namely, (1) ; (2) ; and (3) . The second class of methods weights the reference distribution under each case of the null to form a mixture reference distribution. The third class constructs a composite test statistic using the three p values obtained under each case of the null so that the reference distribution of the composite statistic is approximately . In addition to these existing methods, we developed the Sobel‐comp method belonging to the second class, which uses a corrected mixture reference distribution for Sobel's test statistic. We performed extensive simulation studies to compare all six methods belonging to these three classes in terms of the false positive rates (FPRs) under the null hypothesis and the true positive rates under the alternative hypothesis. We found that the second class of methods which uses a mixture reference distribution could best maintain the FPRs at the nominal level under the null hypothesis and had the greatest true positive rates under the alternative hypothesis. We applied all methods to study the mediation mechanism of DNA methylation sites in the pathway from adult socioeconomic status to glycated hemoglobin level using data from the Multi‐Ethnic Study of Atherosclerosis (MESA). We provide guidelines for choosing the optimal mediation hypothesis testing method in practice and develop an R package medScan available on the CRAN for implementing all the six methods.


  • Open Access

    Optimal diagnostic test allocation strategy during the COVID‐19 pandemic and beyond

    by Jiacong Du, Lauren J Beesley, Seunggeun Lee, Xiang Zhou, Walter Dempsey, Bhramar Mukherjee

    Timely diagnostic testing for active SARS‐CoV‐2 viral infections is key to controlling the spread of the virus and preventing severe disease. A central public health challenge is defining test allocation strategies with limited resources. In this paper, we provide a mathematical framework for defining an optimal strategy for allocating viral diagnostic tests. The framework accounts for imperfect test results, selective testing in certain high‐risk patient populations, practical constraints in terms of budget and/or total number of available tests, and the purpose of testing. Our method is not only useful for detecting infections, but can also be used for long‐time surveillance to detect new outbreaks. In our proposed approach, tests can be allocated across population strata defined by symptom severity and other patient characteristics, allowing the test allocation plan to prioritize higher risk patient populations. We illustrate our framework using historical data from the initial wave of the COVID‐19 outbreak in New York City. We extend our proposed method to address the challenge of allocating two different types of diagnostic tests with different costs and accuracy, for example, the RT‐PCR and the rapid antigen test (RAT), under budget constraints. We show how this latter framework can be useful to reopening of college campuses where university administrators are challenged with finite resources for community surveillance. We provide a R Shiny web application allowing users to explore test allocation strategies across a variety of pandemic scenarios. This work can serve as a useful tool for guiding public health decision‐making at a community level and adapting testing plans to different stages of an epidemic. The conceptual framework has broader relevance beyond the current COVID‐19 pandemic.